Societal impact assessment

Abundance Potential

Natural Shigella Exposure Could Complicate Vaccine Trial Results, Simulation Suggests

Assessment takeaway

Unknown · insufficient evidence

The target is a specific trial-design approach, and the simulations support a bounded potential improvement in scientific capability. Effects on health, affordability, fairness, and the environment are not established. The broader societal benefit remains speculative because the finding has not been validated in vaccine trials and depends on uncertain assumptions.

AI-generated · Not editor reviewedAssessed 2026-11-04Rubric abundance-potential-v1

This describes conditional potential, not a probability or measured outcome. Unknown values are not zero, and harms are not subtracted from the total.

Assessment scope

Development
Use active surveillance for Shigella infection, paired with a single-outcome analysis, in vaccine trials to estimate efficacy in a fully susceptible population.
Baseline
The other modeled combinations of symptom-based or active infection surveillance with single-outcome or recurrent-outcome analyses.
Population
Hypothetical trials enrolling healthy, immune-naive infants; findings may be less applicable to participants with prior immunity or different serotype exposure.
Geography
Simulated low-, medium-, and high-burden settings, with the study framed around low-resource settings.
Target assumptions
The potential benefit depends on the simulation reflecting trial conditions and on surveillance detecting asymptomatic infections. The modeled bias is sensitive to uncertain natural-history and immunity assumptions.

Five dimensions

Human wellbeing
Unknown · The study models trial-estimation methods; it does not establish that this approach improves health outcomes or vaccine effectiveness in people. Sources: evidence-363
Affordability and access
Unknown · The supplied evidence does not assess vaccine affordability, availability, or access.
Reach and fairness
Unknown · The simulations include different infection-burden settings, but the evidence does not assess who would benefit or whether access would be equitable. Sources: evidence-363
Environment and resources
Unknown · Environmental effects and resource use were not evaluated in the supplied evidence.
Scientific capability
2/4 · The simulations identify a trial surveillance and analysis approach that consistently recovered the modeled efficacy across examined scenarios, providing a potentially useful, bounded capability for planning and interpreting Shigella vaccine trials. This remains conditional on assumptions about natural history and immunity that the authors say rely on limited data. Sources: evidence-363, evidence-364, evidence-366

Evidence, confidence and timing

Evidence maturity

Finding: Early speculative. The finding comes from simulated hypothetical trials, not a trial evaluating a vaccine or validating the approach in practice.

Societal benefit: Early speculative. Any broader benefit depends on future trials using the approach and on subsequent vaccine evidence; this study does not demonstrate health or access outcomes.

Confidence: Low. The simulations support what the approach did under the scenarios examined, but the results depend on uncertain natural-history and immunity assumptions, and the supplied article identifies itself as an uncorrected proof.

Conditional time horizon: Unknown. The evidence describes planned future trials but gives no timeline for adoption of this approach or for any resulting societal benefit.

Possible benefits

  • Could help trial teams estimate vaccine efficacy in a fully susceptible population more accurately under the modeled conditions, supporting trial planning and interpretation. Sources: evidence-363, evidence-364

Risks and possible harms

  • Active infection surveillance, including detection of asymptomatic infections, may be difficult to implement because it requires regular testing. Affected groups: Trial participants and teams in settings where regular infection testing is difficult to conduct. Sources: evidence-364
  • If the simulation assumptions do not match trial populations, estimates or expectations based on the modeled approach may not transfer reliably. Affected groups: Trial teams and populations whose infection histories, serotypes, or prior immunity differ from the modeled scenarios. Sources: evidence-366

Distribution and adoption

Who might be excluded

  • The simulations did not account for Shigella serotype differences or variation in participants’ prior immunity, limiting support for applying the findings to those populations. Sources: evidence-366

Adoption barriers

  • Active infection surveillance requires detecting infections, including asymptomatic ones, and may be difficult to implement in practice. Sources: evidence-364
  • Limited published data on Shigella natural history and immunity make it difficult to establish how closely the model assumptions match future trial populations. Sources: evidence-366

Assumptions and conditions that could change the assessment

  • The modeled infection rates, natural history, and protection from infection are sufficiently similar to those in future trial settings. Sources: evidence-366
  • Surveillance can detect infections that do not produce symptoms, as required by the approach that performed best in the simulations. Sources: evidence-364
  • Evidence from actual trials, along with improved data on natural history, serotypes, and prior immunity, could change confidence in how well the modeled approach generalizes. Sources: evidence-366

Citations

  1. evidence-363 · Analysis of the impact of naturally-acquired immunity on Shigella vaccine performance to inform clinical trials: A simulation-based modeling study · A; v; n; i; k; a; ; B; .; ; A; m; i; n · 10.1371/journal.pmed.1004878 · Captured publisher article text · Open source
  2. evidence-364 · Analysis of the impact of naturally-acquired immunity on Shigella vaccine performance to inform clinical trials: A simulation-based modeling study · A; v; n; i; k; a; ; B; .; ; A; m; i; n · 10.1371/journal.pmed.1004878 · Captured publisher article text · Open source
  3. evidence-366 · Analysis of the impact of naturally-acquired immunity on Shigella vaccine performance to inform clinical trials: A simulation-based modeling study · A; v; n; i; k; a; ; B; .; ; A; m; i; n · 10.1371/journal.pmed.1004878 · Captured publisher article text · Open source